Guillain-Barre Syndrome Clinical Trial
Official title:
Effect of Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases in Mechanically Ventilated Patients, a Randomized Clinical Trail
Verified date | April 2024 |
Source | Cairo University |
Contact | Elmasry |
Phone | 01005587119 |
egydodo[@]rocketmail.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the current study is to compare the effect of ventilator trigger sensitivity adjustment versus threshold inspiratory muscle training on arterial blood gases in mechanically ventilated patients.
Status | Recruiting |
Enrollment | 45 |
Est. completion date | May 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Difficult to wean Guillain barre patients who have been on MV for at least 48 hours. Difficult to wean subjects have been defined as those who fail the first spontaneous breathing trial (SBT)and may require up to 3 SBTs or up to 7 d from the first attempt to achieve successful weaning (BĀ“eduneau G. et al.,2017) and (Annia F. et al.,2019). 2. Age: >18 years. 3. Both sexes will be included. 4. Ventilator mode: Pressure support mode with FiO2= 0.5, positive end expiratory pressure (PEEP) will be<8-10cm/H2Oand respiratory rate < 25. 5. Conscious oriented patient with Glasgow coma score =13. 6. Alertness will be titrated to a Riker Sedation Agitation Score of 4. 7. PH>7.25, arterial oxygen saturation >90%. 8. Cardiovascular stability. 9. Maximal inspiratory pressure from 15 to 30 cm H2O and able to trigger spontaneous breaths on ventilator. Exclusion Criteria: 1. Persistent hemodynamic instability as life threatening arrhythmias, acute heart failure. 2. Severe breathlessness, when spontaneously breathing. 3. Any progressive neuromuscular disease that would interfere with responding to inspiratory muscle training (non-stationary course). 4. Spinal cord injury. 5. Skeletal pathology (scoliosis, flail chest, spinal instrumentation) that would seriously impair the movement of the chest wall and ribs. 6. Patients on heavy sedation and respiratory muscle paralysis. 7. High peak airway pressure (barotraumas). 8. BMI = 40. |
Country | Name | City | State |
---|---|---|---|
Egypt | Kasr Al Ainy School of Medicine | Cairo |
Lead Sponsor | Collaborator |
---|---|
Cairo University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PH | To measure PH | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Primary | PaO2 | To measure partial pressure of oxygen | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Primary | PaCO2 | To measure partial pressure of carbon dioxide | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Primary | HCO3 | To measure bicarbonate | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | Rapid shallow breathing index | To measure respiratory endurance | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | The Horowitz index | To measure PaO2 /FiO2 ratio | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | Glasgow coma scale | To measure level of consciousness | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | Riker Sedation-Agitation Scale | Arousal/sedation assessment | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | Respiratory rate | Number of breath cycles per minute | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | Minute ventilation | The amount of air that enters the lungs per minute. | Pre intervention and immediate post intervention, through study completion, an average of two weeks | |
Secondary | Weaning success rate | Number of patients weaning from MV | post intervention at the end of the study, an average of two weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04053452 -
Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
|
N/A | |
Recruiting |
NCT02582853 -
sCD163 as a Potential Biomarker in Guillain- Barré Syndrome
|
N/A | |
Completed |
NCT00056810 -
Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine
|
Phase 2 | |
Completed |
NCT05104762 -
IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05630313 -
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
|
||
Recruiting |
NCT03801135 -
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
|
N/A | |
Active, not recruiting |
NCT01655394 -
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
|
N/A | |
Completed |
NCT04927598 -
Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
|
||
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Not yet recruiting |
NCT04092140 -
Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
|
||
Not yet recruiting |
NCT04550611 -
Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome
|
N/A | |
Withdrawn |
NCT03268304 -
Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
|
||
Not yet recruiting |
NCT05701189 -
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
|
Phase 2 | |
Withdrawn |
NCT02459808 -
Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome
|
N/A | |
Completed |
NCT04752566 -
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
|
Phase 3 | |
Completed |
NCT05292690 -
An Assistive Powered Wheelchair: Stage 2 Trial
|
||
Not yet recruiting |
NCT06300359 -
Prognostic Indicators of Gullian-Barre Syndrome
|
||
Completed |
NCT00575653 -
Safety Study of GBS Following Menactra Meningococcal Vaccination
|
N/A | |
Completed |
NCT05491096 -
Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome
|
N/A | |
Not yet recruiting |
NCT05114941 -
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
|
N/A |